Leerink Partnrs Reiterates Outperform Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Partnrs in a report released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 […]

Related Keywords

China ,Switzerland ,Swiss ,Cantor Fitzgerald ,Leerink Partnrs ,Lexicon Pharmaceuticals ,News Ratings For Lexicon Pharmaceuticals Daily ,Needham Company ,Victory Capital Management Inc ,Lexicon Pharmaceuticals Inc ,Swiss National Bank ,Lexicon Pharmaceuticals Company Profile ,China Universal Asset Management Co ,Pinnacle Associates Ltd ,Lexicon Pharmaceuticals Trading ,Get Free Report ,Capital Management ,National Bank ,China Universal Asset Management ,Universal Asset Management ,Lexicon Pharmaceuticals Daily ,Nasdaq Lxrx ,Lxrx ,Medical ,52887210 ,Reiterated Rating ,